triazoles has been researched along with Central Nervous System Diseases in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Finkelman, MA; Katragkou, A; Kovanda, LL; Maung, BBW; Moradi, PW; Naing, E; Petraitiene, R; Petraitis, V; Sussman-Straus, GE; Walsh, TJ | 1 |
| Alsaad, AM; Koren, G | 1 |
| Costantino, F; Di Biasi, C; Friederici, D; Notheis, G; Pasquino, AM; Tarani, L; Venditti, M; Wintergerst, U | 1 |
| Boss, C; Brisbare-Roch, C; Gatfield, J; Jenck, F | 1 |
| Bouvier-Alias, M; Calvez, V; Canestri, A; Clavel, C; Katlama, C; Lascaux, AS; Lelievre, JD; Levy, Y; Melica, G; Peytavin, G | 1 |
| Engin, E; Liu, J; Rudolph, U | 1 |
| Cunha, RA; Dall'Igna, OP; Dall'lgna, OP; Lara, DR; Porciúncula, LO; Souza, DO | 1 |
| Muñoz, P; Pascual, J | 1 |
| Antoniadis, A; Braimi, M; Dermitzakis, E; Kioumi, A; Papadakis, E; Tsitouridis, I; Vyzantiadis, TA | 1 |
| Crofton, KM | 1 |
| Anand, VS; Dewan, MJ | 1 |
| Arndt, CA; Balis, FM; McCully, CL; Pizzo, PA; Poplack, DG; Walsh, TJ | 1 |
3 review(s) available for triazoles and Central Nervous System Diseases
| Article | Year |
|---|---|
Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials.
Topics: Anticonvulsants; Central Nervous System Diseases; Disorders of Excessive Somnolence; Dizziness; Drug Resistance; Epilepsy; Fatigue; Headache; Humans; Randomized Controlled Trials as Topic; Risk; Triazoles | 2014 |
Orexin receptor antagonists: a new concept in CNS disorders?
Topics: Acetamides; Azepines; Central Nervous System Diseases; Humans; Intracellular Signaling Peptides and Proteins; Isoquinolines; Neuropeptides; Orexin Receptors; Orexins; Patents as Topic; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Signal Transduction; Triazoles | 2010 |
α2-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders.
Topics: Alcoholism; Animals; Anxiety; Central Nervous System Diseases; Chronic Pain; Cognition Disorders; Depression; GABA-A Receptor Agonists; Humans; Polymorphism, Genetic; Pyridazines; Receptors, GABA-A; Schizophrenia; Substance-Related Disorders; Triazoles | 2012 |
9 other study(ies) available for triazoles and Central Nervous System Diseases
| Article | Year |
|---|---|
Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of Exserohilum rostratum meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Ascomycota; Central Nervous System Diseases; Disease Management; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Nitriles; Phaeohyphomycosis; Pyridines; Rabbits; Triazoles | 2021 |
Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl.
Topics: Antifungal Agents; Central Nervous System Diseases; Child; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Follow-Up Studies; Humans; Mucormycosis; Nose Diseases; Orbital Diseases; Time Factors; Treatment Outcome; Triazoles | 2009 |
Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Cyclohexanes; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Triazoles | 2010 |
Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Caffeine; Cells, Cultured; Central Nervous System Diseases; Cerebellum; Neurons; Neuroprotective Agents; Peptide Fragments; Rats; Rats, Wistar; Receptor, Adenosine A2A; Theophylline; Triazines; Triazoles | 2003 |
Correlation between lipophilicity and triptan outcomes.
Topics: Central Nervous System Diseases; Chemical Phenomena; Chemistry, Physical; Humans; Indoles; Migraine Disorders; Oxazolidinones; Piperidines; Serotonin Receptor Agonists; Statistics as Topic; Sumatriptan; Treatment Outcome; Triazoles; Tryptamines | 2005 |
Rhino-cerebral zygomycosis resistant to antimycotic treatment: a case report.
Topics: Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Central Nervous System Diseases; Drug Resistance, Fungal; Fatal Outcome; Humans; Male; Methylprednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines; Rhinitis; Rhizopus; Triazoles; Voriconazole; Zygomycosis | 2009 |
A structure-activity relationship for the neurotoxicity of triazole fungicides.
Topics: Animals; Central Nervous System Diseases; Dose-Response Relationship, Drug; Fungicides, Industrial; Hyperkinesis; Male; Rats; Structure-Activity Relationship; Triazoles | 1996 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |
Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.
Topics: Animals; Central Nervous System Diseases; Cryptococcosis; Fluconazole; Macaca mulatta; Male; Triazoles | 1988 |